Vemlidy (tenofovir alafenamide) / Gilead - LARVOL DELTA

Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B study. (PubMed, Am J Gastroenterol) - "BR rates were similar with ETV and TAF, while VR and CR were higher with TAF though the difference was modest (<5% overall, 7-9% in high HBV DNA or ALT groups). Antiviral selection between TAF vs. ETV should be based mainly on cost, side effect profile, and patient preference."

Journal • Hepatitis B • Infectious Disease • Inflammation

Monitoring adherence and renal safety of nucleos(t)ide analogues for patients with chronic hepatitis B. (PubMed, Clin Transl Gastroenterol) - "In this real-world cohort, adherence to recommended monitoring for CHB patients on NAs was suboptimal. ETV, TDF and TAF demonstrated comparable renal safety profiles over 3 years."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation • Nephrology • Renal Disease

Unveiling low level viremia in chronic hepatitis B: challenges and new horizons. (PubMed, Front Cell Infect Microbiol) - "Current management strategies emphasize optimizing antiviral regimens, such as switching to tenofovir alafenamide (TAF) or combining therapies with pegylated interferon-alpha (Peg-IFN-α)...This will allow for the validation of synergistic effects between metabolic interventionsand immunotherapy, thereby advancing personalized precision medicine. This review systematically synthesizes the epidemiological characteristics, pathogenesis, influencing factors, prognosis, and clinical management advancements of LLV, aiming to provide novel perspectives for optimizing therapeutic strategies and translational research."

Journal • Review • Fibrosis • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • Solid Tumor • IFNA1

Partial post-exposure protection by topical inserts containing tenofovir alafenamide fumarate/elvitegravir in a macaque model of rectal SHIV infection. (PubMed, J Infect Dis) - "Here, we show that the same inserts provide significant post-exposure protection (82.9% efficacy) when applied four hours after SHIV exposure. Our findings further support the ongoing clinical development of TAF/EVG inserts for on-demand HIV prevention."

Journal • Human Immunodeficiency Virus • Infectious Disease

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial. (PubMed, Hepatol Commun) - P3 | "The use of preemptive TAF therapy did not reduce the risk of HBsAg reverse seroconversion; however, the findings should be interpreted with caution as the study was underpowered due to slow enrolment leading to early termination. Low-level HBV DNA elevations were not associated with HBV reactivation. Thus, close HBsAg and ALT monitoring are adequate in HBsAg-negative patients undergoing rituximab-based chemotherapy."

Clinical • Journal • Hematological Malignancies • Hepatitis B • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Effects of Integrase Strand Transfer Inhibitors Versus Non-INSTI Regimen Exposures in Pregnancy Outcomes, Maternal Weight Gain, and Human Immunodeficiency Virus Viral Suppression. (PubMed, J Womens Health (Larchmt)) - "Background: Integrase strand transfer inhibitors (INSTIs) with and without tenofovir alafenamide fumarate (TAF) are recommended in first-line regimens for pregnant people living with human immunodeficiency virus (PWH), with mixed data emerging on pregnancy outcomes and maternal weight gain... Any INSTI exposure did not significantly increase odds of undetectable viral load at delivery. Any TAF exposure was significantly associated with undetectable viral load and hypertensive disorder at delivery."

Journal • Hepatology • Human Immunodeficiency Virus • Infectious Disease

HBV-PHICHIT: Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach (clinicaltrials.gov) - P4 | N=6000 | Not yet recruiting | Sponsor: The Task Force for Global Health

New P4 trial • Hepatitis B • Infectious Disease • Inflammation

The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in Participants with HIV-associated Tuberculosis. (PubMed, J Acquir Immune Defic Syndr) - "When combined with rifampicin, ART containing standard-dose TAF resulted in higher TFV-DP concentrations than TDF-based ART in participants with HIV-associated tuberculosis, supporting its use with rifampicin-containing tuberculosis therapy."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - P2 | N=150 | Active, not recruiting | Sponsor: Gilead Sciences | Trial primary completion date: Dec 2025 ➔ Sep 2026

Trial primary completion date • Hepatitis B • Infectious Disease • Inflammation • B2M

Optimized strategy of switching to tenofovir alafenamide fumarate treatment for nucleos(t)ide analogue experienced patients with chronic hepatitis B. (PubMed, Front Med (Lausanne)) - "No serious adverse events (SAEs) or deaths related to adverse events were observed. This real-world study suggests that switching to TAF is an effective and well-tolerated therapeutic strategy for NA-experienced CHB patients with PRT or LLV, offering a promising approach for treatment optimization."

Journal • Hepatitis B • Infectious Disease • Inflammation

Effectiveness and safety of tenofovir alafenamide in chronic hepatitis B patients over 30 years old with positive hepatitis B virus DNA: a double-center retrospective study. (PubMed, Front Med (Lausanne)) - "TAF treatment significantly alleviated the progression of CHB patients over a 96-week follow-up period. TAF remains effective for younger patients or those with normal liver function, providing evidence for further expanding antiviral indications."

Journal • Retrospective data • Chronic Kidney Disease • Hepatitis B • Infectious Disease • Inflammation • Nephrology • Renal Disease

Evaluation of the Efficacy of Tenofovir Alafenamide in Patients with Low-Level Viremia Under Chronic Hepatitis B Treatment. (PubMed, Viruses) - "In this multicenter, retrospective study involving 62 patients, we investigated whether switching from entecavir (ETV) or tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) represents a superior treatment strategy for patients with chronic hepatitis B (CHB) experiencing low-level viremia (LLV). This evidence suggests that TAF provides robust virological control in LLV patients and is associated with favorable biochemical improvements. However, due to the study's limitations, the strong assertion that TAF promotes the regression of liver fibrosis and reduces the risk of hepatocellular carcinoma (HCC) must be interpreted with caution."

Journal • Retrospective data • Fibrosis • Hepatitis B • Hepatocellular Cancer • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Solid Tumor

Real-World Effectiveness of Antiviral Prophylaxis for Preventing Hepatitis B Virus (HBV) Reactivation in Patients Undergoing Immunosuppressive Therapy. (PubMed, Viruses) - "Prophylaxis consisted of entecavir in 76.4%, tenofovir alafenamide in 13.1%, and tenofovir disoproxil fumarate in 10.5%. HBV reactivation occurred in only one patient, who had discontinued treatment. These findings emphasize the importance of HBV screening and timely prophylactic antiviral therapy in patients undergoing immunosuppression to effectively prevent HBV reactivation."

Journal • Real-world evidence • Retrospective data • Hepatitis B • Infectious Disease • Inflammation

Navigating the Latest Hepatitis B Virus Reactivation Guidelines. (PubMed, Diseases) - "Entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are all highly effective in preventing HBV reactivation during immunosuppression and all are considered to be economically viable options for HBVr high risk patients. When selecting among these agents, safety considerations-particularly renal and bone toxicity-and insurance coverage remain the primary factors directing clinical decision-making."

Journal • Review • Hepatitis B • Infectious Disease • Inflammation • Transplantation

Successful Treatment of Progressive Multifocal Leukoencephalopathy With Tenofovir Alafenamide Fumarate. (PubMed, Neurol Neuroimmunol Neuroinflamm) - "This case demonstrates temporal association between TAF initiation and virologic clearance of JCV, suggesting potential antiviral activity."

Journal • CNS Disorders • Infectious Disease • Multiple Sclerosis • Rare Diseases

Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation. (PubMed, World J Gastrointest Oncol) - "Among patients with hepatitis B cirrhosis-related HCC, TDF and TAF are associated with lower 2-year and 3-year HCC recurrence rates after curative RFA treatment compared with ETV. However, there were no significant differences in 3-year mortality rates between the ETV, TDF, and TAF groups."

Journal • Fibrosis • Hepatitis B • Hepatocellular Cancer • Immunology • Infectious Disease • Liver Cancer • Oncology • Solid Tumor • AFP

Factors Associated With TDF-to-TAF Switching in Chronic Hepatitis B: A Nationwide Cohort Study in South Korea. (PubMed, J Infect Chemother) - "In this nationwide cohort study, the TAF switching rate among patients receiving TDF was 1.4% within one year of TAF's reimbursement approval in South Korea. Switching was significantly associated with renal disease, bone disease, age ≥60 years, hypertension, and ACEi/ARB use. Although the higher switching rate in patients with renal or bone disease aligns with reimbursement criteria, other at-risk groups not currently covered may benefit from earlier access."

Journal • Cardiovascular • Hepatitis B • Hepatocellular Cancer • Hepatology • Hypertension • Infectious Disease • Inflammation • Nephrology • Oncology • Orthopedics • Renal Disease • Solid Tumor

Evaluation of tenofovir alafenamide- versus tenofovir disoproxil fumarate-containing regimens on renal outcomes: systematic literature review and meta-analysis. (PubMed, BMC Nephrol) - No abstract available

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Tenofovir alafenamide fumarate use for HIV pre-exposure prophylaxis and weight gain. (PubMed, Sci Rep) - "Daily oral pre-exposure prophylaxis (PrEP), including emtricitabine/tenofovir disoproxil fumarate (TDF) and emtricitabine/tenofovir alafenamide fumarate (TAF), is a key strategy for HIV prevention. TAF-only (β = 2.532, 95%CI 0.708-4.356) and TDF-TAF (β = 2.756, 95%CI 0.890-4.621) were associated with significantly increased weight gain compared to TDF-only use. Closer monitoring of weight gain is recommended for individuals using TAF to prevent HIV."

Journal • Human Immunodeficiency Virus • Infectious Disease

Recurrence of HBV Reactivation after Allogeneic Hematopoietic Transplantation in Recipients with Resolved HBV Infection: A Nation-Wide Multicenter Retrospective Study (ASH 2023) - "All patients received preemptive NA (entecavir 65, tenofovir alafenamide 6, tenofovir 1). Careful monitoring of HBV-DNA is important even after the discontinuation of NA in the case with HBV reactivation after allo-HSCT because multiple reactivations could occur. A prospective randomized trial of the HB vaccine after allo-HSCT for preventing HBV reactivation is now ongoing (UMIN000034113)."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Adult T-Cell Leukemia-Lymphoma • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatology • Immunology • Infectious Disease • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Crossing Borders for Organs: A Case of Transplant Tourism (KIDNEY WEEK 2025) - "She was given cyclosporine, mycophenolate, and prednisolone, without prophylactic antimicrobials or transplant education...Decompensated liver disease: Prior to transplant, her HBV and HDV were well controlled on tenofovir alafenamide and bulevirtide...As recipients return home, the responsibility of care falls on local transplant physicians, raising ethical concerns about beneficence versus a sense of complicity in organ trade. Physicians should document transplant circumstances, consult ethics, and ensure continued care even if it warrants transferring the patient."

Clinical • Cardiovascular • Chronic Kidney Disease • Cough • Cytomegalovirus Infection • Glomerulonephritis • Hepatitis B • Hepatology • Infectious Disease • Influenza • Lupus Nephritis • Nephrology • Respiratory Diseases • Solid Organ Transplantation • Transplantation • Tuberculosis • Urinary Incontinence • ERBB3

Tenofovir Alafenamide Fumarate-Associated Fanconi Syndrome (KIDNEY WEEK 2025) - "The patient had been stable on darunavir, ritonavir, and raltegravir, but this was changed to a combined bictegravir-emtricitabine-tenofovir alafenamide for simplicity just prior to his presentation. His development of acute and severe electrolyte disturbances after initiation of TAF is concerning for acute worsening of preexisting Fanconi syndrome. This case highlights that while TAF is generally considered safer, there is still risk of renal toxicity, particularly when renal tubular dysfunction is already present."

Chronic Kidney Disease • Fatigue • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Diseases • Nephrology • Orthopedics • Renal Disease

Impact of Tenofovir Alafenamide (TAF)-Containing Regimens vs. Regimens Without TAF on Kidney Outcomes in HIV Treatment: Systematic Literature Review and Meta-Analysis (KIDNEY WEEK 2025) - "Conclusion Our findings demonstrated potential renal safety advantages of TAF over both non-TAF and TFV-sparing ART for HIV-1 treatment. Changes of eGFR in TAF vs Non-TFV Over Time *Heterogeneity unavailable as only one study at 144 weeks SD for standard deviation."

Retrospective data • Review • Human Immunodeficiency Virus • Infectious Disease

Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices During Pregnancy and Postpartum. (PubMed, Clin Pharmacokinet) - "Our semi-mechanistic model provides a framework for understanding pregnancy-associated pharmacokinetic changes and supports future research to refine dosing strategies for HIV treatment and prevention in pregnancy."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease

Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results from IMPAACT 2010/VESTED. (PubMed, J Acquir Immune Defic Syndr) - "Breastmilk transfer of DTG, TAF, and TFV is low and results in minimal systemic exposure in breastfed infants. The clinical relevance of infant exposure to low concentrations of these antiretrovirals - particularly DTG - is unknown but should be considered in the context of the risk of drug resistance in infants who acquire HIV."

Journal • Human Immunodeficiency Virus • Infectious Disease